A Phase 1b Study of Radiprodil in Participants With GRIN-Related Neurodevelopmental Disorder Caused by Non-Gain-of-Function Variants (4sight)

November 10, 2026 updated by: GRIN Therapeutics, Inc.

A Multicenter, Randomized, Double-Blinded, Placebo-Controlled, Phase 1b Study With an Open-Label Extension to Assess the Safety, Tolerability, Pharmacokinetics, and Effect of Radiprodil in Participants With GRIN-Related Neurodevelopmental Disorder Caused by Variants Characterized as Non-Gain-of-Function

This is a multinational, multicenter, randomized, double-blinded, placebo-controlled, Phase 1b study with an open-label extension (OLE) to assess safety, tolerability, PK, and potential efficacy of radiprodil for the treatment of GRIN-related neurodevelopmental disorder (GRIN-NDD) in children with a genetic variant characterized as non-gain-of-function.

This study will consist of Part A (blinded, placebo-controlled) and Part B (blinded transition followed by an OLE).

Participants will be randomized in a 2:1 ratio to receive active drug (radiprodil) or matching placebo (Part A) and stratified by functional characterization (either indeterminant, LoF, or no effect). Following completion of Part A, all eligible participants (including those previously on placebo) may continue into the open-label extension period (Part B) to receive radiprodil.

The placebo-controlled portion is expected to be approximately 17 weeks for participants in Part A and at least 12 months for participants in Part B.

Study Overview

Status

Not yet recruiting

Conditions

Intervention / Treatment

Detailed Description

Participants are assigned in a 2:1 ratio to receive either radiprodil or placebo during Part A with the opportunity to receive radiprodil in the Part B OLE.

This study is divided into the following parts:

Part A: Randomized, double-blind, placebo-controlled

  • Screening/Observation Period: To assess eligibility (approximately 5 weeks)
  • Titration Period (approximately 4 weeks): Titration of radiprodil or placebo to target dose
  • Maintenance Period (Part A): Target dose of radiprodil or placebo maintained for 8 weeks
  • Tapering and Follow-up Period: Gradual decrease and Follow-up Period for participants not entering Part B

Part B: Open-label safety follow-up period

  • Blinded Titration Period (approximately 4 weeks): Titration of radiprodil to target dose
  • Open-Label Treatment Period: Participants will continue to receive radiprodil until such time as either the participant withdraws/is withdrawn from the study, Sponsor terminates the study, or market access is available
  • Tapering and Follow-up Period: Gradual decrease and follow-up observation period for participants upon leaving the study

Study Type

Interventional

Enrollment (Estimated)

27

Phase

  • Phase 1

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

1 month to 18 years (Child, Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

Part A, Participant:

  • Diagnosed with GRIN-NDD with GRIN1, GRIN2A, GRIN2B, or GRIN2D gene variants known to result in a functional characterization that is loss of function, indeterminant, or no effect
  • Inadequately controlled seizures of any type with clinically significant EEG abnormalities per EEG collected within 12 months of Screening or during the Screening Period
  • Receiving at least 1 standard antiseizure medication (ASM)
  • On a stable dose of standard ASM for at least 4 weeks prior to screening and should remain on stable dose throughout study participation
  • Nonpharmacological treatments such as ketogenic diet should remain stable throughout study participation
  • Participant's caregivers are willing and able to complete entries in the eDiary on a daily basis and have demonstrated compliance

Part B, Participant:

- Has completed Part A and is eligible to continue study participation according to the judgment of the Investigator and Sponsor.

Exclusion Criteria:

PART A, Participant:

  • Has clinically relevant medical, neurologic, or psychiatric condition and/or behavioral disorder (including those related to GRIN-NDD) that would preclude or jeopardize participant's safe participation or study drug administration or the conduct of the study according to the judgement of the investigator or sponsor.
  • Is receiving >4 standard ASMs at screening
  • Has a body weight of less than 5 kg at screening
  • Participant or caregiver is unwilling or unable to comply with all study procedures for the duration of the study.
  • Has clinically significant laboratory or ECG abnormalities according to the judgment of the Investigator or Sponsor
  • Has severe hepatic dysfunction (Child-Pugh grade C)
  • Has a history of brain surgery within 6 months of randomization for epilepsy or any other reason
  • Is receiving treatment with prohibited concomitant drugs such as agonists or antagonists of the glutamate receptor, including but not limited to felbamate, memantine, and perampanel
  • Is receiving treatment with a strong CYP3A4 inhibitor (eg, itraconazole or some antimicrobials that are strong inhibitors) that has not been discontinued at least 5 half-lives prior to the planned first dose of radiprodil
  • Has received any prior gene therapy
  • Is on treatment with hormonal therapy such as adrenocorticotrophic hormone or prednisolone

Part B Participant:

  • Has clinically relevant medical, neurologic, or psychiatric condition and/or behavioral disorder (including those related to GRIN-NDD) that would preclude or jeopardize participant's safe participation of study drug administration or the conduct of the study according to the judgement of the investigator or sponsor.
  • Participant or caregiver is unwilling or unable to comply with all study procedures for the duration of the study.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Triple

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Radiprodil oral suspension

Liquid suspension of radiprodil, at varying concentrations depending on participant's weight.

The following dose-escalation regimen (twice daily [BID]) will be used:

Titration Period Visit 1 (Visit T1): Dose 1, Visit T2: Dose 2, Visit T3: Dose 3, Visit T4: Maintenance Dose.

Radiprodil oral suspension

Placebo Comparator: Placebo-to-match radiprodil oral suspension

Liquid suspension of placebo matching radiprodil oral suspension and dose-escalation regimen.

Placebo-to-match radiprodil oral suspension

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Adverse Events (AEs)
Time Frame: From Screening through study completion, including Part A (approximately 17 weeks), Part B (anticipated at least 12 months), and follow-up (14 [+7] days after the last dose including taper or End of Study Visit, whichever is later).

Number and percentage of participants experiencing adverse events (AEs). AEs will be assessed by frequency, type, severity, and duration. Treatment-emergent AEs will be coded using the Medical Dictionary for Regulatory Activities (MedDRA) and summarized by System Organ Class and Preferred Term.

From Screening through study completion, including Part A (approximately 17 weeks), Part B (anticipated at least 12 months), and follow-up (14 [+7] days after the last dose including taper or End of Study Visit, whichever is later).
Serious Adverse Events (SAEs)
Time Frame: From Screening through study completion, including Part A (approximately 17 weeks), Part B (anticipated at least 12 months), and follow-up (14 [+7] days after the last dose including taper or End of Study Visit, whichever is later).

Number and percentage of participants experiencing serious adverse events (SAEs). SAEs will be assessed by frequency, type, severity, and duration, including treatment-emergent SAEs and SAEs considered related to investigational product.

From Screening through study completion, including Part A (approximately 17 weeks), Part B (anticipated at least 12 months), and follow-up (14 [+7] days after the last dose including taper or End of Study Visit, whichever is later).
Adverse Drug Reactions (ADRs)
Time Frame: From Screening through study completion, including Part A (approximately 17 weeks), Part B (anticipated at least 12 months), and follow-up (14 [+7] days after the last dose including taper or End of Study Visit, whichever is later).

Number and percentage of participants experiencing adverse drug reactions (ADRs). ADRs will be assessed by frequency, type, severity, and duration and summarized by functional characterization, study part, and overall.

From Screening through study completion, including Part A (approximately 17 weeks), Part B (anticipated at least 12 months), and follow-up (14 [+7] days after the last dose including taper or End of Study Visit, whichever is later).
Change From Baseline in Blood Pressure
Time Frame: From Baseline through study completion, including Part A (approximately 17 weeks) and Part B (anticipated at least 12 months).

Change from Baseline in blood pressure (mmHg), assessed at scheduled study visits. Observed values and changes from Baseline will be summarized using descriptive statistics.

From Baseline through study completion, including Part A (approximately 17 weeks) and Part B (anticipated at least 12 months).
Change From Baseline in Pulse Rate
Time Frame: From Baseline through study completion, including Part A (approximately 17 weeks) and Part B (anticipated at least 12 months).

Change from Baseline in pulse rate (beats per minute), assessed at scheduled study visits. Observed values and changes from Baseline will be summarized using descriptive statistics.

From Baseline through study completion, including Part A (approximately 17 weeks) and Part B (anticipated at least 12 months).
Physical Examination Findings
Time Frame: From Baseline through study completion, including Part A (approximately 17 weeks) and Part B (anticipated at least 12 months).

Number and percentage of participants with abnormal physical or neurological examination findings. Findings will be listed, and findings indicative of adverse events will be included in adverse event summaries.

From Baseline through study completion, including Part A (approximately 17 weeks) and Part B (anticipated at least 12 months).
Change From Baseline in ECG Pulse Rate
Time Frame: From Baseline through study completion, including Part A (approximately 17 weeks) and Part B (anticipated at least 12 months).

Change from Baseline in pulse rate measured by 12-lead electrocardiogram (ECG), expressed in beats per minute (bpm).

From Baseline through study completion, including Part A (approximately 17 weeks) and Part B (anticipated at least 12 months).
Change From Baseline in ECG RR Interval
Time Frame: From Baseline through study completion, including Part A (approximately 17 weeks) and Part B (anticipated at least 12 months).

Change from Baseline in the RR interval measured by 12-lead electrocardiogram (ECG), expressed in milliseconds (ms).

From Baseline through study completion, including Part A (approximately 17 weeks) and Part B (anticipated at least 12 months).
Change From Baseline in ECG PR Interval
Time Frame: From Baseline through study completion, including Part A (approximately 17 weeks) and Part B (anticipated at least 12 months).

Change from Baseline in the PR interval measured by 12-lead electrocardiogram (ECG), expressed in milliseconds (ms).

From Baseline through study completion, including Part A (approximately 17 weeks) and Part B (anticipated at least 12 months).
Change From Baseline in ECG QRS Duration
Time Frame: From Baseline through study completion, including Part A (approximately 17 weeks) and Part B (anticipated at least 12 months).

Change from Baseline in QRS duration measured by 12-lead electrocardiogram (ECG), expressed in milliseconds (ms).

From Baseline through study completion, including Part A (approximately 17 weeks) and Part B (anticipated at least 12 months).
Change From Baseline in ECG QT Interval
Time Frame: From Baseline through study completion, including Part A (approximately 17 weeks) and Part B (anticipated at least 12 months).

Change from Baseline in the QT interval measured by 12-lead electrocardiogram (ECG), expressed in milliseconds (ms).

From Baseline through study completion, including Part A (approximately 17 weeks) and Part B (anticipated at least 12 months).
Change From Baseline in ECG QTcF Interval
Time Frame: From Baseline through study completion, including Part A (approximately 17 weeks) and Part B (anticipated at least 12 months).

Change from Baseline in the QT interval corrected using Fridericia's formula (QTcF), measured by 12-lead electrocardiogram (ECG), expressed in milliseconds (ms).

From Baseline through study completion, including Part A (approximately 17 weeks) and Part B (anticipated at least 12 months).
Clinically Significant Changes in Clinical Laboratory Parameters
Time Frame: From Baseline through study completion, including Part A (approximately 17 weeks) and Part B (anticipated at least 12 months).

Number and percentage of participants with clinically significant abnormalities or changes in clinical laboratory parameters, including hematology, serum chemistry, and coagulation assessments. Laboratory values and changes from Baseline will be summarized, and clinically significant abnormal values listed separately.

From Baseline through study completion, including Part A (approximately 17 weeks) and Part B (anticipated at least 12 months).
Emergence of New Seizure Types
Time Frame: From Baseline through study completion, including Part A (approximately 17 weeks) and Part B (anticipated at least 12 months).

Number and percentage of participants experiencing new seizure types compared with Baseline. Emergence of new seizure types will be tabulated overall and by seizure type at scheduled assessments.

From Baseline through study completion, including Part A (approximately 17 weeks) and Part B (anticipated at least 12 months).
Occurrence of Suicidal Ideation
Time Frame: From Baseline through study completion, including Part A (approximately 17 weeks) and Part B (anticipated at least 12 months).

Number and percentage of participants experiencing suicidal ideation at any post-Baseline assessment, based on the Columbia-Suicide Severity Rating Scale (C-SSRS) or investigator assessment, as appropriate for the participant.

From Baseline through study completion, including Part A (approximately 17 weeks) and Part B (anticipated at least 12 months).
Occurrence of Suicidal Behavior
Time Frame: From Baseline through study completion, including Part A (approximately 17 weeks) and Part B (anticipated at least 12 months).

Number and percentage of participants experiencing suicidal behavior at any post-Baseline assessment, based on the Columbia-Suicide Severity Rating Scale (C-SSRS) or investigator assessment, as appropriate for the participant.

From Baseline through study completion, including Part A (approximately 17 weeks) and Part B (anticipated at least 12 months).

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Plasma Concentration of Radiprodil
Time Frame: From first dose through study completion, including Part A (12 weeks of treatment) and Part B (anticipated at least 12 months).

Plasma concentrations of radiprodil will be measured at predefined pharmacokinetic (PK) sampling timepoints.

From first dose through study completion, including Part A (12 weeks of treatment) and Part B (anticipated at least 12 months).
Change From Baseline in SERIAS Green Light Days
Time Frame: Baseline (4-week Observation Period) to the end of Part A Maintenance Period (Week 8).

Change from Baseline to the end of the Part A Maintenance Period in the number of green light days, assessed using the Seizure-Related Impact Assessment Scale (SERIAS) and captured in the daily electronic diary (eDiary).

Baseline (4-week Observation Period) to the end of Part A Maintenance Period (Week 8).
Change From Baseline in SERIAS Yellow Light Days
Time Frame: Baseline (4-week Observation Period) to the end of Part A Maintenance Period (Week 8).

Change from Baseline to the end of the Part A Maintenance Period in the number of yellow light days, assessed using SERIAS and captured in the daily eDiary.

Baseline (4-week Observation Period) to the end of Part A Maintenance Period (Week 8).
Change From Baseline in SERIAS Red Light Days
Time Frame: Baseline (4-week Observation Period) to the end of Part A Maintenance Period (Week 8).

Change from Baseline to the end of the Part A Maintenance Period in the number of red light days, assessed using SERIAS and captured in the daily eDiary.

Baseline (4-week Observation Period) to the end of Part A Maintenance Period (Week 8).
Change From Baseline in Total Countable Seizure Frequency per 28 Days
Time Frame: Baseline (last 4 weeks before randomization) through Part A Maintenance Period (8 weeks).

Change from Baseline in total countable seizure frequency normalized to 28 days during the Part A Maintenance Period (Weeks 1 through 8), as recorded in the daily seizure eDiary.

Baseline (last 4 weeks before randomization) through Part A Maintenance Period (8 weeks).
Change From Baseline in EEG Spike Rate
Time Frame: Baseline through Part A Maintenance Period (Weeks 1 through 8).

Change from Baseline in electroencephalogram (EEG) spike rate, expressed as spikes per hour, during the Part A Maintenance Period.

Baseline through Part A Maintenance Period (Weeks 1 through 8).
Change From Baseline in EEG Background Activity
Time Frame: Baseline through Part A Maintenance Period (Weeks 1 through 8).

Change from Baseline in electroencephalogram (EEG) background activity during the Part A Maintenance Period.

Baseline through Part A Maintenance Period (Weeks 1 through 8).
Percentage of Participants With at Least 50% Reduction in Total Countable Seizure Frequency
Time Frame: Baseline (last 4 weeks before randomization) to the end of Part A Maintenance Period (8 weeks).

Percentage of participants achieving at least a 50% reduction in total countable seizure frequency per 28 days from Baseline (the last 4 weeks before randomization) to the entire Part A Maintenance Period.

Baseline (last 4 weeks before randomization) to the end of Part A Maintenance Period (8 weeks).
Percentage of Participants With at Least 50% Reduction in Total Seizure Frequency
Time Frame: Baseline through Part A and Part B, as assessed.

Percentage of participants achieving at least a 50% reduction in total seizure frequency compared with Baseline.

Baseline through Part A and Part B, as assessed.
Percent Change From Baseline in Total Countable Seizure Frequency
Time Frame: Baseline through Part A and Part B, as assessed.

Percent change from Baseline in total countable seizure frequency normalized to 28 days. Percent change is calculated relative to the Baseline seizure frequency.

Baseline through Part A and Part B, as assessed.
Proportion of Seizure-Free Days
Time Frame: Baseline through Part A and Part B, as assessed.

Proportion of days without seizures during the assessment period, based on seizure data recorded in the daily eDiary.

Baseline through Part A and Part B, as assessed.
Longest Interval of Seizure Freedom
Time Frame: Baseline through Part A and Part B, as assessed.

Longest consecutive interval without seizures during the assessment period, based on seizure data recorded in the daily eDiary.

Baseline through Part A and Part B, as assessed.

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Investigators

  • Study Director: Michelle Pritikin, GRIN Therapeutics, Inc.
  • Study Director: Aneeta Saxena, GRIN Therapeutics, Inc.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Estimated)

December 1, 2026

Primary Completion (Estimated)

October 1, 2027

Study Completion (Estimated)

December 1, 2027

Study Registration Dates

First Submitted

November 5, 2026

First Submitted That Met QC Criteria

November 10, 2026

First Posted (Actual)

November 17, 2026

Study Record Updates

Last Update Posted (Actual)

November 17, 2026

Last Update Submitted That Met QC Criteria

November 10, 2026

Last Verified

November 1, 2026

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • RAD-GRIN-102

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

UNDECIDED

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

Yes

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.